Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 8,172 shares at $12.31 ($101K) on 2024-03-06, disclosed to the SEC on 2024-03-08.
Scheduled sale ($101k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.31 | 4,086 | $50K | 50.0% |
| 2 | $12.31 | 4,086 | $50K | 50.0% |
| Total | $12.31 avg | 8,172 | $101K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |